GNOM Global X - Genomics & Biotechnology ETF
Quote as of Oct 09, 2026 20:00 UTC · Market data delayed approximately 15–20 minutes unless otherwise indicated.
| Previous Close | 65.83 | Day Range | 66.35 – 68.75 |
| 52-Week Range | 40.17 – 74.19 | Volume | 24.34K |
| Avg Volume | 33.49K | AUM | $103.7M (Oct 12, 2026) |
| Expense Ratio | 0.50% | Yield (TTM) | 0.94% |
| NAV | 68.47 | Premium/Discount | +0.41% indicative |
| Inception | Apr 05, 2019 | Holdings | 50 |
| Issuer | Global X | Exchange | NASDAQ |
| Category | Biotech | Index Tracked | Not stated in source data |
| CUSIP | 37960A214 | ISIN | US37960A2143 |
| Management | Passive / index-tracking (per issuer description) | ||
About this ETF
The Global X Genomics & Biotechnology ETF, known by its ticker GNOM, aims to closely track the performance of the Solactive Genomics Index, reflecting both its price appreciation and any generated income. This mirroring occurs before the deduction of the ETF's internal fees and expenses.
Description from the fund data provider · profile as of Oct 12, 2026.
Price Chart
Daily closing prices (price return, not total return). Comparison lines are normalized to percent change from the range start. Source: Financial Modeling Prep.
Performance
| 1M | 3M | 6M | YTD | 1Y | 3Y* | 5Y* | 10Y* | Incep.* | |
|---|---|---|---|---|---|---|---|---|---|
| Price return | +9.56% | +21.36% | +56.61% | +51.23% | +63.46% | +19.25% | -4.01% | — | +1.50% |
| Total return | +9.56% | +21.36% | +56.78% | +51.40% | +65.74% | +19.80% | -3.74% | — | +1.69% |
* Annualized. Total return uses the dividend-adjusted price series (distributions reinvested); price return uses unadjusted closes. Performance through Oct 09, 2026. Past performance does not guarantee future results.
Fees
| Net expense ratio | 0.50% | Annual cost of a $10,000 investment | $50.00 |
Illustrative calculation only: expense ratio × $10,000. It excludes trading costs, bid/ask spreads, taxes and changes in investment value. Gross vs. net expense details and any fee waivers are in the prospectus.
Holdings
Holdings as of Oct 10, 2026 · portfolio reporting date from the data provider; holdings are not live positions. 52 rows in database.
| # | Holding | Ticker | Weight | Shares | Market Value |
|---|---|---|---|---|---|
| 1 | MODERNA INC | MRNA | 11.33% | 53.96K | $12.1M |
| 2 | TWIST BIOSCIENCE CORP | TWST | 6.87% | 46.05K | $7.4M |
| 3 | 10X GENOMICS INC-CLASS A | TXG | 6.67% | 88.62K | $7.1M |
| 4 | ILLUMINA INC | ILMN | 5.97% | 22.99K | $6.4M |
| 5 | NATERA INC | NTRA | 5.40% | 14.43K | $5.8M |
| 6 | GUARDANT HEALTH INC | GH | 5.24% | 33.49K | $5.6M |
| 7 | GENSCRIPT BIOTECH CORP | 1548.HK | 4.49% | 889.62K | $4.8M |
| 8 | BIO-TECHNE CORP | TECH | 3.46% | 51.20K | $3.7M |
| 9 | VERTEX PHARMACEUTICALS INC | VRTX | 3.27% | 6.86K | $3.5M |
| 10 | QIAGEN N.V. | QGEN | 3.18% | 75.06K | $3.4M |
| 11 | BIOMARIN PHARMACEUTICAL INC | BMRN | 2.83% | 55.40K | $3.0M |
| 12 | CRISPR THERAPEUTICS AG | CRSP | 2.65% | 53.17K | $2.8M |
| 13 | CARIS LIFE SCIENCES INC | CAI | 2.61% | 94.32K | $2.8M |
| 14 | VERACYTE INC | VCYT | 2.57% | 60.99K | $2.8M |
| 15 | BIONTECH SE-ADR | BNTX | 2.50% | 27.63K | $2.7M |
| 16 | ARROWHEAD PHARMACEUTICALS IN | ARWR | 2.38% | 40.57K | $2.5M |
| 17 | PRAXIS PRECISION MEDICINES I | PRAX | 2.16% | 8.90K | $2.3M |
| 18 | CAREDX INC | CDNA | 2.13% | 35.83K | $2.3M |
| 19 | LEGEND BIOTECH CORP-ADR | LEGN | 2.01% | 115.68K | $2.2M |
| 20 | ELI LILLY & CO | LLY | 1.78% | 1.61K | $1.9M |
| 21 | BEAM THERAPEUTICS INC | BEAM | 1.75% | 72.81K | $1.9M |
| 22 | GILEAD SCIENCES INC | GILD | 1.59% | 11.28K | $1.7M |
| 23 | BILLIONTOONE INC CL A | BLLN | 1.42% | 15.48K | $1.5M |
| 24 | SAREPTA THERAPEUTICS INC | SRPT | 1.30% | 78.14K | $1.4M |
| 25 | GENEDX HOLDINGS CORP | WGS | 1.27% | 20.16K | $1.4M |
| 26 | ASTRAZENECA PLC | AZN.L | 1.13% | 7.65K | $1.2M |
| 27 | INTELLIA THERAPEUTICS INC | NTLA | 1.07% | 87.90K | $1.1M |
| 28 | ULTRAGENYX PHARMACEUTICAL IN | RARE | 1.05% | 72.98K | $1.1M |
| 29 | DANAHER CORP | DHR | 1.02% | 4.98K | $1.1M |
| 30 | VIR BIOTECHNOLOGY INC | VIR | 0.99% | 90.34K | $1.1M |
| 31 | UNIQURE NV | QURE | 0.92% | 43.41K | $980.6K |
| 32 | BRISTOL-MYERS SQUIBB CO | BMY | 0.87% | 15.69K | $927.4K |
| 33 | STOKE THERAPEUTICS INC | STOK | 0.84% | 36.51K | $903.3K |
| 34 | PERSONALIS INC | PSNL | 0.80% | 53.80K | $860.8K |
| 35 | MARAVAI LIFESCIENCES HLDGS-A | MRVI | 0.57% | 82.32K | $612.4K |
| 36 | PACIFIC BIOSCIENCES OF CALIF | PACB | 0.46% | 211.94K | $493.8K |
| 37 | WAVE LIFE SCIENCES INC | WVE | 0.39% | 121.47K | $420.3K |
| 38 | AGILENT TECHNOLOGIES INC | A | 0.35% | 2.17K | $370.8K |
| 39 | FULGENT GENETICS INC | FLGT | 0.31% | 15.45K | $335.9K |
| 40 | BRUKER CORP | BRKR | 0.31% | 5.67K | $333.4K |
| 41 | PRIME MEDICINE INC | PRME | 0.28% | 74.34K | $296.6K |
| 42 | MYRIAD GENETICS INC | MYGN | 0.28% | 68.53K | $295.4K |
| 43 | REGENXBIO INC | RGNX | 0.27% | 36.23K | $292.4K |
| 44 | MESA LABORATORIES INC | MLAB | 0.26% | 2.22K | $282.6K |
| 45 | QUEST DIAGNOSTICS INC | DGX | 0.24% | 1.10K | $254.5K |
| 46 | BENITEC BIOPHARMA INC | BNTC | 0.21% | 25.68K | $227.8K |
| 47 | EDITAS MEDICINE INC | EDIT | 0.21% | 76.60K | $222.1K |
| 48 | ROCKET PHARMACEUTICALS INC | RCKT | 0.19% | 80.64K | $206.4K |
| 49 | STANDARD BIOTOOLS INC | LAB | 0.15% | 239.02K | $164.8K |
| 50 | CARIBOU BIOSCIENCES INC | CRBU | 0.04% | 95.42K | $43.9K |
| 51 | OTHER PAYABLE & RECEIVABLES | — | 0.01% | 7.31K | $7.3K |
| 52 | CASH | — | -0.05% | -49.09K | -$49.1K |
Click a ticker to see every ETF that owns it.
Sector Exposure
Geographic Exposure
Country weights as reported by the data provider. Developed/emerging/frontier labels follow the classification on the Methodology page. Currency hedged: No hedging indicated in the fund name.
Distributions
| Yield (TTM) | 0.94% | Paid (last 12 months) | $0.6491 |
| Frequency | Semi-Annual | SEC yield | Not provided by our data source; see the issuer page |
| Last ex-date | Jun 29, 2026 | Last payment | $0.0579 (Jul 07, 2026) |
| Growth 1Y | +7740.26% | Growth 3Y / 5Y (ann.) | — / — |
| Ex-date | Record | Pay date | Amount |
|---|---|---|---|
| Jun 29, 2026 | Jun 29, 2026 | Jul 07, 2026 | $0.0579 |
| Dec 30, 2025 | Dec 30, 2025 | Jan 07, 2026 | $0.5912 |
| Jun 27, 2025 | Jun 27, 2025 | Jul 07, 2025 | $0.0083 |
| Dec 30, 2021 | Dec 31, 2021 | Jan 07, 2022 | $0.0070 |
| Dec 30, 2020 | Dec 31, 2020 | Jan 08, 2021 | $0.0324 |
Trailing distribution yield = last 12 months of cash ÷ current price. It is NOT the SEC 30-day yield and distributions are not guaranteed to continue. The difference explained →
Risk Statistics
| Volatility 1Y / 3Y | 32.82% / 31.75% | Sharpe 1Y / 3Y | 2.31 / 0.761 |
| Max drawdown 1Y / 3Y | -18.16% / -43.29% | Sortino 1Y | 4.04 |
| Beta vs S&P 500 (3Y) | 1.19 | Correlation vs S&P 500 (1Y) | 0.449 |
| Downside deviation 1Y | 18.80% | Risk-free rate used | 4.05% (3M T-bill, FRED) |
Computed by ETF Explorer from daily dividend-adjusted closes; volatility and drawdown are annualized/period figures; S&P 500 exposure proxied by SPY. As of Oct 12, 2026. Formulas →
Liquidity
| Volume today | 24.34K | Average volume | 33.49K |
| AUM | $103.7M | Premium/Discount | +0.41% |
| Bid/Ask spread | Not provided by our data source. Check your broker's quote screen; spreads are widest at the open and close. | ||
Premium/discount compares the delayed market price with the last reported NAV: an indicative figure, not the official closing premium/discount. How ETF liquidity works →
Fund Flows (estimated)
| Period | Est. net flow | % of starting AUM | AUM start → end |
|---|---|---|---|
| 1 Day | $0.00 | 0.00% | $103.7M → $103.7M |
| 1 Month | $129.4K | +0.14% | $93.7M → $103.7M |
| 1 Week | $6.2M | +6.00% | $102.6M → $103.7M |
ETF Explorer estimate: change in reported AUM minus the market-move effect, from our own daily snapshots. Not official issuer creation/redemption data.
Official Fund Resources
External links open the issuer's site or SEC EDGAR in a new tab. The prospectus and official documents are always the authoritative source; review them before investing.
Latest News for GNOM
No articles mention this fund directly in the last 7 days; showing general ETF coverage.
Guided help: AUM is fund size. The expense ratio is the yearly cost baked into returns. NAV is the value of what the fund owns per share; the market price can sit slightly above (premium) or below (discount) it. Total return assumes distributions were reinvested. Every dataset shows its own as-of date because holdings, assets and quotes update on different schedules.